Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q1 2022
Holdings as of Mar 31, 2022, filed May 16, 2022. Long positions only; changes compare share counts with Q4 2021.
- Positions
- 39
- −4 vs. Q4 2021
- Portfolio value
- $201.8M
- −$59.3M (−22.7%) vs. Q4 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ASNDAscendis Pharma A/S | SPONSORED ADR | 140,000 | $16.4M | 8.1% | −50,000−26.3% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 1,700,000 | $12.7M | 6.3% | 00.0% | Unchanged | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 250,000 | $12.7M | 6.3% | −75,000−23.1% | Reduced | History |
| MRUSMerus N.V. | COM | 400,000 | $10.6M | 5.2% | +50,000+14.3% | Added | History |
| FOLDAmicus Therapeutics, Inc. | COM | 1,100,000 | $10.4M | 5.2% | +600,000+120.0% | Added | History |
| SRRASierra Oncology, Inc. | COM NEW | 325,000 | $10.4M | 5.2% | +75,000+30.0% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 300,000 | $10.2M | 5.1% | −50,000−14.3% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 466,403 | $8.62M | 4.3% | −33,597−6.7% | Reduced | History |
| KRTXKaruna Therapeutics, Inc. | COM | 60,000 | $7.61M | 3.8% | +60,000 | New | History |
| ISEEIVERIC bio, Inc. | COM | 450,000 | $7.57M | 3.8% | −175,000−28.0% | Reduced | History |
| ARVNArvinas, Inc. | COM | 110,000 | $7.40M | 3.7% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 300,000 | $7.25M | 3.6% | +50,000+20.0% | Added | History |
| KZRKezar Life Sciences, Inc. | COM | 400,000 | $6.65M | 3.3% | +150,000+60.0% | Added | History |
| CTICCti Biopharma Corp | COM | 1,300,000 | $6.07M | 3.0% | +100,000+8.3% | Added | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 350,000 | $5.69M | 2.8% | +350,000 | New | History |
| RAPTRAPT Therapeutics, Inc. | COM | 250,000 | $5.50M | 2.7% | −100,000−28.6% | Reduced | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 100,000 | $4.39M | 2.2% | +100,000 | New | History |
| AXSMAxsome Therapeutics, Inc. | COM | 94,500 | $3.91M | 1.9% | +94,500 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 225,000 | $3.91M | 1.9% | −75,000−25.0% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 50,000 | $3.91M | 1.9% | −50,000−50.0% | Reduced | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 750,000 | $3.74M | 1.9% | 00.0% | Unchanged | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 80,000 | $3.69M | 1.8% | 00.0% | Unchanged | History |
| DSGNDesign Therapeutics, Inc. | COM | 200,000 | $3.23M | 1.6% | +65,000+48.1% | Added | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 200,000 | $3.17M | 1.6% | −225,000−52.9% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 100,000 | $3.06M | 1.5% | 00.0% | Unchanged | History |
| RLMDRelmada Therapeutics, Inc. | COM | 100,000 | $2.70M | 1.3% | −100,000−50.0% | Reduced | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 150,000 | $2.55M | 1.3% | −50,000−25.0% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 125,000 | $2.15M | 1.1% | −200,000−61.5% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 120,000 | $2.02M | 1.0% | −50,000−29.4% | Reduced | History |
| NMTR9 Meters Biopharma, Inc. | COM | 3,250,000 | $1.95M | 1.0% | 00.0% | Unchanged | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 85,000 | $1.87M | 0.9% | −33,344−28.2% | Reduced | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 473,562 | $1.80M | 0.9% | −430,663−47.6% | Reduced | History |
| CYPHCypherpunk Technologies Inc. | COM | 993,714 | $1.74M | 0.9% | −356,286−26.4% | Reduced | History |
| MRTXMirati Therapeutics, Inc. | COM | 20,000 | $1.64M | 0.8% | −10,000−33.3% | Reduced | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 1,315,154 | $1.63M | 0.8% | −684,846−34.2% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM | 686,599 | $1.58M | 0.8% | +686,599 | New | History |
| PRDSPardes Biosciences, Inc. | COM | 85,000 | $614.0K | 0.3% | +35,000+70.0% | Added | History |
| LRMRLarimar Therapeutics, Inc. | COM | 100,000 | $405.0K | 0.2% | −125,000−55.6% | Reduced | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 75,000 | $303.0K | 0.2% | −220,000−74.6% | Reduced | History |
Options (3)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q4 2021 (9)
Positions held at the end of Q4 2021 that are gone from this filing.
| Security | Class | Shares in Q4 2021 | Value in Q4 2021 | % of portfolio in Q4 2021 | History |
|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 30,000 | $5.09M | 1.9% | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 210,000 | $4.64M | 1.8% | History |
| Bellus Health Inc New07987C204 | COM NEW | 450,000 | $3.62M | 1.4% | – |
| KURAKura Oncology, Inc. | COM | 225,000 | $3.15M | 1.2% | History |
| GHRSGH Research PLC | ORDINARY SHARES | 100,000 | $2.33M | 0.9% | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 60,000 | $1.76M | 0.7% | History |
| IMUXImmunic, Inc. | COM | 165,000 | $1.58M | 0.6% | History |
| RETAReata Pharmaceuticals Inc | CL A | 55,000 | $1.45M | 0.6% | History |
| CABACabaletta Bio, Inc. | COM | 135,000 | $512.0K | 0.2% | History |